⌕
Kodiak Sciences · KOD · Nasdaq
Tenet 16 · Weak
Compare
$100.73−9.41%At closeTenet 16 · Weak
$100.73−10.46 (−9.41%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Kodiak Sciences (KOD) Stock

Kodiak Sciences (KOD) closed at $100.73 on Nov 16, 2026; its Tenet Score is 16 of 100 against 313 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

34 figures withheld by our checks. Each blank figure names its reason.

Key stats

Previous close
$100.73
Nov 16, 2026
Market cap
$7.3B
share price × the latest quarter's diluted weighted-average share count (vendor)
52-week range
18.05 – 112.79
low → high · as of close, Nov 13, 2026
Tenet Score
16/100
Weak · 313 Healthcare peers

Industry: Health Services

Kodiak Sciences Inc scores 16/100. Weak. Value is the soft spot versus 313 Healthcare peers. Insufficient inputs: Tenet 16 is built from 3 of 4 pillars, from 35% of its inputs. The pillars showing a dash had no data.

Tenet Score · vs sector

n=313
16/ 100
Weak
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
0
Quality
4
Health
45
Growth
—

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
Growth omitted — no data yet.
ValueFQualityFHealthDGrowth—MomentumA+
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
Not meaningful: the company made a loss.
P/B
578.4×
price to book value
Outside the range we rank; ranked at the edge of the range.
P/S
—
no P/S on file
ROE
−1361%
return on equity
Outside the range we rank; ranked at the edge of the range.
Operating margin
—
no operating margin on file
Net margin
—
Not meaningful: revenue is too small to measure a margin against.
Current ratio
1.70
current assets to liabilities
Net debt / EBITDA
—
Not meaningful: EBITDA is zero or negative.
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About Kodiak Sciences Inc

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is…

Composite computed Nov 13, 2026 · peer basis: Healthcare (n=313) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 65 US ETFs · top wrappers by weightSee all ETFs holding KOD →

Similar-sized companies in Health Services

The 10 companies in this industry closest in market cap, as of Nov 13, 2026.

What sector and industry is Kodiak Sciences in?

Kodiak Sciences is in the Healthcare sector and the Health Services industry.

What is Kodiak Sciences' Tenet Score?

Kodiak Sciences' Tenet Score is 16 out of 100, ranked against 313 Healthcare peers as of Nov 13, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.